Dr. Geert Cauwenbergh, sincerely, it's time to step aside, and bring in someone new, who can turn RXII around. Sadly, something is not working, even though siRNA technology and immunotherapy agents technology is doing well, but could be better with a Big Pharm partner. Just a thought. Things have to change. Enough said. A RXII believer and a share holder.